{"id":1928,"date":"2020-03-20T15:07:29","date_gmt":"2020-03-20T19:07:29","guid":{"rendered":"https:\/\/md.rcm.upr.edu\/actu5401\/?page_id=1928"},"modified":"2021-12-13T09:56:09","modified_gmt":"2021-12-13T13:56:09","slug":"publicaciones","status":"publish","type":"page","link":"https:\/\/md.rcm.upr.edu\/actu5401\/publicaciones\/","title":{"rendered":"PUBLICACIONES"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column][vc_column_text]<strong>2018<\/strong><\/p>\n<ul>\n<li>Women have enhanced bone loss associated with phosphaturia and CD4 cell restoration during initial antiretroviral therapy.<br \/>\nEnlace: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30134291\">https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30134291<\/a><\/li>\n<li>Similar Low Rates of HCV Recurrence in HCV\/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS).<br \/>\nEnlace: <a href=\"https:\/\/academic.oup.com\/ofid\/article\/5\/6\/ofy103\/5032747\">https:\/\/academic.oup.com\/ofid\/article\/5\/6\/ofy103\/5032747<\/a><\/li>\n<li>High Baseline Anal Human Papillomavirus and Abnormal Anal Cytology in a Phase 3 Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Individuals Older Than 26 Years: ACTG 5298.<br \/>\nEnlace: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29528986\">https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29528986<\/a><\/li>\n<li>ACTG A5353: a pilot study of dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA &lt; 500,000 copies\/mL.<br \/>\nEnlace: <a href=\"https:\/\/academic.oup.com\/cid\/article\/66\/11\/1689\/4743559\">https:\/\/academic.oup.com\/cid\/article\/66\/11\/1689\/4743559<\/a><\/li>\n<li>Desde Puerto Rico podr\u00edan desarrollar nanopart\u00edculas ante nueva era cl\u00ednica contra el VIH.<br \/>\nEnlace: <a href=\"https:\/\/medicinaysaludpublica.com\/desde-puerto-rico-podrian-desarrollar-nanoparticulas-ante-nueva-era-clinica-contra-el-vih\/-with\">https:\/\/medicinaysaludpublica.com\/desde-puerto-rico-podrian-desarrollar-nanoparticulas-ante-nueva-era-clinica-contra-el-vih\/-with<\/a><\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_column_text]<strong>2017<\/strong><\/p>\n<ul>\n<li>Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults.<br \/>\nEnlace: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5427981\/\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5427981\/<\/a><\/li>\n<li>Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women A Phase 2 Randomized Trial.<br \/>\nEnlace: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5667908\/\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5667908\/<\/a><\/li>\n<li>Dr. Jorge Santana: A la caza de los virus que afectan a los puertorrique\u00f1os.<br \/>\nEnlace: <a href=\"https:\/\/medicinaysaludpublica.com\/dr-jorge-santana-dedica-su-carrera-a-la-investigacion-contra-el-sida\/\">https:\/\/medicinaysaludpublica.com\/dr-jorge-santana-dedica-su-carrera-a-la-investigacion-contra-el-sida\/<\/a><\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_column_text]<strong>2016<\/strong><\/p>\n<ul>\n<li>Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069\/ACTG A5305).<br \/>\nEnlace: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5790146\/\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5790146\/<\/a><\/li>\n<li>Se prolonga la vida de los pacientes de SIDA en Puerto Rico<br \/>\nEnlace: <a href=\"https:\/\/medicinaysaludpublica.com\/se-prologa-la-vida-de-los-pacientes-de-sida-en-puerto-rico\/\">https:\/\/medicinaysaludpublica.com\/se-prologa-la-vida-de-los-pacientes-de-sida-en-puerto-rico\/<\/a><\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_column_text]<strong>2015<\/strong><\/p>\n<ul>\n<li>HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled Trial.<br \/>\nEnlace: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4681296\/\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4681296\/<\/a><\/li>\n<li>Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257<br \/>\nEnlace: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4660025\/\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4660025\/<\/a><\/li>\n<li>Less Bone Loss WithMaraviroc-Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.<br \/>\nEnlace: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4560904\/\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4560904\/<\/a><\/li>\n<li>Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1\u2013Infected Adults Receiving Long-term Antiretroviral Therapy.<br \/>\nEnlace: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4721905\/\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4721905\/<\/a><\/li>\n<li>Reductions in Plasma Cystatin C after Initiation of Antiretroviral Therapy are Associated with Reductions in Inflammation: ACTG A5224s.<br \/>\nEnlace: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4445470\/pdf\/nihms657473.pdf\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4445470\/pdf\/nihms657473.pdf<\/a><\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_column_text]<strong>2014<\/strong><\/p>\n<ul>\n<li>Metabolic syndrome in relation to cardiorespiratory fitness, active and sedentary behavior in HIV+ Hispanics with and without lipodystrophy.<br \/>\nEnlace: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4329015\/pdf\/nihms-657179.pdf\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4329015\/pdf\/nihms-657179.pdf<\/a><\/li>\n<li>La resistenciabacteriana: enemigo de la salud p\u00fablica. Revista puertorrique\u00f1a de Medicina y Salud P\u00fablica.<br \/>\nEnlace: <a href=\"https:\/\/medicinaysaludpublica.com\/la-resistencia-bacteriana-enemigo-de-la-salud-publica-2\/\">https:\/\/medicinaysaludpublica.com\/la-resistencia-bacteriana-enemigo-de-la-salud-publica-2\/<\/a><\/li>\n<li>Puerto Rico frente al SIDA. Revista puertorrique\u00f1a de Medicina y Salud P\u00fablica.<br \/>\nEnlace: <a href=\"https:\/\/medicinaysaludpublica.com\/puerto-rico-frente-al-sida-entrevista-al-dr-jorge-santana-director-de-actu-e-investigador-principal\/\">https:\/\/medicinaysaludpublica.com\/puerto-rico-frente-al-sida-entrevista-al-dr-jorge-santana-director-de-actu-e-investigador-principal\/<\/a><\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_column_text]<strong>2013<\/strong><\/p>\n<ul>\n<li>Nuevos avances en el tratamiento del paciente co-infectado con Hepatitis C y VIH.<\/li>\n<li>Perspectivas e implicaciones clinicas para la estrategia de identificacion y tratamiento temprano.<\/li>\n<li>Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.<br \/>\nEnlace: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3549598\/\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3549598\/<\/a><\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_column_text]<strong>2011<\/strong><\/p>\n<ul>\n<li>Incidence of non-AIDS-defining cancer in antiretroviral treatment-na\u00efve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis.<br \/>\nEnlace: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3121543\/\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3121543\/<\/a><\/li>\n<li>Abacavir\/lamivudine versus tenofovir DF\/emtricitabine as part of combination regimens for initial treatment of HIV: final results.<br \/>\nEnlace: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3173503\/\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3173503\/<\/a><\/li>\n<li>Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.<br \/>\nEnlace: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3430716\/\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3430716\/<\/a><\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_column_text]<strong>2010<\/strong><\/p>\n<ul>\n<li>Bone disease in HIV infection: a practical reviewand recommendations for HIV care providers.<br \/>\nEnlcae: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3105903\/\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3105903\/<\/a><\/li>\n<li>Detection of KPC in Acinetobacter spp. in Puerto Rico. Antimicrob Agents Chemother.<br \/>\nEnlcae: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2825984\/pdf\/0899-09.pdf\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2825984\/pdf\/0899-09.pdf<\/a><\/li>\n<li>Prevalence of cardiometabolic risk factors in Hispanics living with HIV.<br \/>\nEnlcae: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3071519\/\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3071519\/<\/a><\/li>\n<li>Uridine supplementation in the treatment of HIV lipoatrophy: Results of ACTG 5229. <a href=\"http:\/\/doi.org\/10.1097\/QAD.0b013e32833ea9bc\">http:\/\/doi.org\/10.1097\/QAD.0b013e32833ea9bc<\/a><\/li>\n<li>ACTG 5197: A Placebo Controlled Trial of Immunization of HIV-1 Infected Persons with a Replication Deficient Ad5 Vaccine Expressing the HIV-1 Core Protein. <a href=\"http:\/\/doi.org\/10.1086\/655468\">http:\/\/doi.org\/10.1086\/655468<\/a><\/li>\n<li>Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial.<br \/>\n<a href=\"http:\/\/doi.org\/10.1086\/651118\">http:\/\/doi.org\/10.1086\/651118<\/a><\/li>\n<li>Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection.<br \/>\nEnlace: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3018341\/\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3018341\/<\/a><\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_column_text]<strong>2009<\/strong><\/p>\n<ul>\n<li>Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial.<br \/>\nEnlace: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2771688\/\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2771688\/<\/a><\/li>\n<li>Fatal granulomatous meningoencephalitis associated to mycobacterium mucogenicum-like microorganism: a case report.<br \/>\nEnlace: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2909603\/\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2909603\/<\/a><\/li>\n<li>Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.<br \/>\nEnlcae: <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa0906768\">https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa0906768<\/a><\/li>\n<li>Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.<br \/>\nEnlace: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19710593\">https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19710593<\/a><\/li>\n<li>Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance.<br \/>\nEnlace: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2706549\/\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2706549\/<\/a><\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_column_text]<strong>2007<\/strong><\/p>\n<ul>\n<li>Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple- nucleoside or efavirenz-containing regimens: ACTG A5166s.<br \/>\nEnlace: <a href=\"https:\/\/academic.oup.com\/jid\/article\/195\/8\/1169\/817058\">https:\/\/academic.oup.com\/jid\/article\/195\/8\/1169\/817058<\/a><\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_column_text]<strong>2006<\/strong><\/p>\n<ul>\n<li>A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024).<br \/>\nEnlace: <a href=\"https:\/\/academic.oup.com\/jid\/article-lookup\/doi\/10.1086\/509508\">https:\/\/academic.oup.com\/jid\/article-lookup\/doi\/10.1086\/509508<\/a><br \/>\nAmdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing currenttherapy (ACTG A5118).<br \/>\nEnlace: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16964830\">https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16964830<\/a><\/li>\n<\/ul>\n<p>[\/vc_column_text][vc_column_text]<strong>2003<\/strong><\/p>\n<ul>\n<li>A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir.<br \/>\nEnlace: <a href=\"https:\/\/miami.pure.elsevier.com\/en\/publications\/a-randomized-trial-of-nelfinavir-and-abacavir-in-combination-with\">https:\/\/miami.pure.elsevier.com\/en\/publications\/a-randomized-trial-of-nelfinavir-and-abacavir-in-combination-with<\/a><\/li>\n<\/ul>\n<p>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_column_text]2018 Women have enhanced bone loss associated with phosphaturia and CD4 cell restoration during initial antiretroviral therapy. Enlace: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30134291 Similar Low Rates of HCV Recurrence in HCV\/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS). Enlace: https:\/\/academic.oup.com\/ofid\/article\/5\/6\/ofy103\/5032747 High Baseline Anal&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-1928","page","type-page","status-publish","hentry","description-off"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/md.rcm.upr.edu\/actu5401\/wp-json\/wp\/v2\/pages\/1928","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/md.rcm.upr.edu\/actu5401\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/md.rcm.upr.edu\/actu5401\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/md.rcm.upr.edu\/actu5401\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/md.rcm.upr.edu\/actu5401\/wp-json\/wp\/v2\/comments?post=1928"}],"version-history":[{"count":0,"href":"https:\/\/md.rcm.upr.edu\/actu5401\/wp-json\/wp\/v2\/pages\/1928\/revisions"}],"wp:attachment":[{"href":"https:\/\/md.rcm.upr.edu\/actu5401\/wp-json\/wp\/v2\/media?parent=1928"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}